|
Market Closed -
Nasdaq
00:00:00 19/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 22.59 USD | -0.83% |
|
-19.52% | -1.72% |
| 08-11 | Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 08-05 | Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis | MT |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| DMRA | Delayed | |
CBOE
| DMRA | Real-time |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Neutral | Bullish |
| Resistance | 26.27 | 32.99 | 34.14 |
| Spread/Res. | -13.91% | -31.45% | -33.76% |
| Spread/Supp. | -0.07% | +24.67% | +78.63% |
| Support | 22.63 | 18.14 | 12.66 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- DMRA Stock
- Charts Damora Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
